Today’s new Top Pick for 2014 is a molecular diagnostic company, whose shares have recently been beaten down, perhaps signaling a buying opportunity.
Myriad Genetics (MYGN)
from Shortex Market Letter
Myriad Genetics (MYGN)
TODAY’S PRICE: $24.25
52 week high 38.27, 52 week low 22.20
Market Cap: $1.79B, EPS: 1.57, P/E: 15.31
The molecular diagnostic/predictive medicine prognostic tests Co. Being bashed by competitors. Out skirting/challenging its patents issues. Side steps its various medicine tests plans and excessive put options: indicative of ending of its slide. Cash in hand over $450M+, no debt. Reversal challenging primary resistance @ (25.30-26.40) and secondary resistance @ (27.60-28.90)
BUYING RANGE: 23-26
NEAR TERM OBJECTIVE: 34
INTER MED OBJECTIVE: 41
STOP LOSS: 21
Joseph Parnes, Shortex Market Letter, www.shortex.com, 800-877-6555, December 13, 2013